# Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)

> **NCT04051268** · PHASE3 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 3071 (actual)

## Conditions studied

- Safety Issues
- Immunogenicity

## Interventions

- **BIOLOGICAL:** Vi-DT Typhoid Conjugate Vaccine
- **BIOLOGICAL:** PQed Typhoid Conjugate Vaccine
- **BIOLOGICAL:** Vi Polysaccharide Vaccine

## Key facts

- **NCT ID:** NCT04051268
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-02
- **Primary completion:** 2021-11-24
- **Final completion:** 2021-12-01
- **Target enrollment:** 3071 (ACTUAL)
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04051268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04051268, "Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04051268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*